Fate Therapeutics (NASDAQ:FATE - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.
Other equities analysts have also issued reports about the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Fate Therapeutics in a research report on Wednesday. Wells Fargo & Company decreased their price target on shares of Fate Therapeutics from $3.50 to $3.00 and set an "equal weight" rating for the company in a research report on Friday. Piper Sandler reiterated an "overweight" rating and set a $8.00 price target (up from $6.00) on shares of Fate Therapeutics in a report on Friday, August 14th. Finally, Wedbush reissued an "outperform" rating and issued a $7.00 price objective on shares of Fate Therapeutics in a report on Tuesday, October 27th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $5.80.
Check Out Our Latest Analysis on FATE
Fate Therapeutics Price Performance
Shares of Fate Therapeutics stock opened at $1.83 on Friday. The stock's 50 day simple moving average is $2.24 and its 200-day simple moving average is $1.97. Fate Therapeutics has a 1-year low of $0.95 and a 1-year high of $3.23. The stock has a market cap of $219.87 million, a P/E ratio of -1.78 and a beta of 2.65.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02. Fate Therapeutics had a negative return on equity of 65.08% and a negative net margin of 1,941.09%. The business had revenue of $1.35 million for the quarter, compared to analyst estimates of $1.14 million. As a group, research analysts expect that Fate Therapeutics will post -1.03 EPS for the current fiscal year.
Hedge Funds Weigh In On Fate Therapeutics
Institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new stake in Fate Therapeutics during the second quarter valued at $19,707,000. Johnson & Johnson acquired a new position in Fate Therapeutics during the 2nd quarter valued at about $9,123,473. Renaissance Technologies LLC lifted its holdings in shares of Fate Therapeutics by 26.0% during the 1st quarter. Renaissance Technologies LLC now owns 2,974,683 shares of the biopharmaceutical company's stock worth $3,570,000 after acquiring an additional 613,802 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Fate Therapeutics by 799.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,311,765 shares of the biopharmaceutical company's stock valued at $3,109,000 after acquiring an additional 1,165,927 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Fate Therapeutics in the second quarter worth $1,552,000. 97.54% of the stock is owned by institutional investors and hedge funds.
About Fate Therapeutics
(
Get Free Report)
Fate Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and autoimmune diseases. The company uses induced pluripotent stem cell (iPSC) technology to create standardized, potentially off-the-shelf immune cell products, including natural killer (NK) cells and T cells.
Its research and development activities include iPSC-derived cell therapies engineered to recognize and attack cancer cells. Fate's pipeline has included candidates such as FT819, an iPSC-derived, CD19-targeted CAR T-cell therapy, along with other investigational NK-cell and T-cell programs.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.
While Fate Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.